These discrepancies suggest the need for larger cohort of patients and appropriate functional studies, in particular to investigate whether the TRAIL levels observed in MS patients are associated with enhanced survival of pathogenic T lymphocytes and other inflammatory markers. The gene discussed is TNFSF10; the disease is myeloid sarcoma.